James P. Carrigan

Partner

Jay Carrigan maintains a general corporate and commercial practice, concentrating on emerging and established companies in the information technology and life sciences, including biotechnology and medical devices, industries. Within the technology sector, his clients include those in the software, computer, robotics and chemical arenas. He assists clients with technology development, technology acquisition, and licensing arrangements; strategic alliances; marketing and distribution arrangements; outsourcing and supply arrangements; and a diverse array of commercial matters. Many of his transactions involve cross-border activities and arrangements. Jay also advises private companies and investors with respect to formation and fund raising matters.

Extended Profile

Jay’s background includes working directly in the technology industry. He served as corporate counsel at Marcam Corporation, a software vendor that delivered ERP solutions to process manufacturers. In this role, he advised and represented Marcam and its subsidiaries in structuring and negotiating transactions to acquire technology, products and services. He also provided advice regarding contractual arrangements with partners, vendors and customers in the US, Europe, Central and South America, and Asia-Pacific regions, and assisted with the implementation of a restructuring plan, including the sale of a subsidiary and the spinoff of another subsidiary.

While serving as assistant general counsel at Tufts-New England Medical Center, Jay helped establish a for-profit subsidiary to develop and market medical outcomes measuring instruments, software and related consulting services. He assisted with industry-sponsored research/licensing transactions and served as counsel to the NEMCH Investigational Review Board. Jay also represented the center and its affiliates in structuring, negotiating and documenting acquisitions of physician practices, software, computer hardware, telecommunications and medical devices.

selected representations

Representative Experience

Eirion Therapeutics in the structuring and negotiation of two License, Development and Commercialization Agreements with Shanghai Haohai Biological Technology Ltd. for three Eirion next-generation prescription product candidates for aesthetic dermatology applications. These agreements include approximately $43 million in development fees, royalties in the high single digit to low twenty range, and up to $444 million in sales milestones
Nevakar in the negotiation of a License Agreement with Zhaoke (Hong Kong) Ophthalmology Pharmaceutical Ltd. for the development and commercialization of Nevakar's NVK-002, a novel topical eye treatment for slowing the progression of myopia in children, in Greater China, South Korea and the Southeast Asian territories. In addition to royalties, this agreement includes upfront fees, development milestones and sales milestones worth up to $102 million
Represented Emendo Biotherapeutics in negotiation of a collaboration and option agreement with Takeda concerning Emendo’s gene editing platform technology
Represented PathMaker Neurosystems in its agreement with WeHealth by Servier to develop and commercialize the first neuromodulation technology for non-invasive treatment of spasticity.
Represented Olix Pharmaceuticals in negotiation of a license and collaboration agreement between Olix and Théa S.A.S. for an RNA interference treatment for dry and wet age-related macular degeneration.
Represented Alexo Therapeutics Limited in structuring, negotiating and documenting in-license of CAR-T technology from Stanford University and related $35 million Series A financing from venBio, Lightstone Ventures, Stanford University, Alexandria Equities and Longevity Fund.
Represented venBio Fund, as lead investor, in the $50 million Series A financing of Precision Biosciences, Inc., a company focused on gene editing platform technology.

Representative Clients

Abeona Therapeuticscme Packet - gene and cell therapy products for the treatment of lysosomal storage diseases
Emendo Biotherapeutics- gene editing technology
QurAlis Corporation precision therapy technology for the treatment of ALS
Sky Computers- embedded supercomputers